HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
薬学研究院  >
雑誌発表論文等  >

Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3

フルテキスト
WoS_81576_narumi.pdf1.54 MBPDF見る/開く
この文献へのリンクには次のURLを使用してください:http://hdl.handle.net/2115/72241

タイトル: Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3
著者: Narumi, Katsuya 著作を一覧する
Sato, Yu 著作を一覧する
Kobayashi, Masaki 著作を一覧する
Furugen, Ayako 著作を一覧する
Kasashi, Kumiko 著作を一覧する
Yamada, Takehiro 著作を一覧する
Teshima, Takanori 著作を一覧する
Iseki, Ken 著作を一覧する
キーワード: famotidine
lansoprazole
methotrexate
organic anion transporter 3
proton pump inhibitor
発行日: 2017年12月
出版者: John Wiley & Sons
誌名: Biopharmaceutics & drug disposition
巻: 38
号: 9
開始ページ: 501
終了ページ: 508
出版社 DOI: 10.1002/bdd.2091
PMID: 28801980
抄録: Methotrexate (MTX) is an antifolate agent used in the treatment of numerous types of cancer, and eliminated by active tubular secretion via organic anion transporter 3 (OAT3). Gastric antisecretory drugs, such as proton pump inhibitors (PPIs) and histamine H-2 receptor antagonists, are widely used among patients with cancer in clinical practice. The aim of the present study was to analyse the potential drug-drug interactions between MTX and gastric antisecretory drugs in high-dose MTX (HD-MTX) therapy. The impact of PPIs on the plasma MTX concentration on 73cycles of HD-MTX therapy was analysed retrospectively in 43 patients. Also investigated was the involvement of OAT3 in PPI-MTX drug interaction in an in vitro study using human OAT3 expressing HEK293 cells. In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48h (0.38 vs. 0.15mol l(-1), respectively, p=0.000018) and 72h (0.13 vs. 0.05mol l(-1), respectively, p=0.0002) compared with patients who did not receive a PPI (but received famotidine). Moreover, in vitro experiments demonstrated that PPIs (esomeprazole, lansoprazole, omeprazole and rabeprazole) inhibited hOAT3-mediated uptake of MTX in a concentration-dependent manner (IC50 values of 0.40-5.5 m), with a rank order of lansoprazole > esomeprazole > rabeprazole > omeprazole. In contrast to PPIs, famotidine showed little inhibitory effect on hOAT3-mediated MTX uptake. These results demonstrated that co-administration of PPI, but not famotidine, could result in a pharmacokinetic interaction that increases the plasma MTX levels, at least in part, via hOAT3 inhibition.
Rights: This is the peer reviewed version of the following article: http://onlinelibrary.wiley.com/doi/10.1002/bdd.2091/abstract;jsessionid=E46DE0BF53C85C966B7A8B8CBD8B31EC.f02t01, which has been published in final form at 10.1002/bdd.2091. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
資料タイプ: article (author version)
URI: http://hdl.handle.net/2115/72241
出現コレクション:雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

提供者: 鳴海 克哉

 

本サイトに関するご意見・お問い合わせは repo at lib.hokudai.ac.jp へお願いします。 - 北海道大学